Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US, page-148

Personally, I'm not remotely concerned about cash for the (potentially approvable -> marketable) EU PIIb trial at present; it's a back-of-mind thought because I'm looking forward to:

1. potentially more analyst updates (Wilsons + Morgans yet to come)
2. EU PIP feed back
3. potentially more analyst updates (whole gamut again?)
4. new indications (come on!)
5. potentially more analyst updates (whole gamut again?)

I plan on seeing where we're sitting after that, but my (long) bet is that we'll be laughing at the 20c days. If we need to raise capital at that point (no partner and.or no deal for new indications), fine.

I guess we'll see how that pans out

Good luck guys!